06 April 2026Conditions: Vestibular Schwannoma Sponsors: Akouos, Inc.; Eli Lilly and Company Enrolling by invitation
19 March 2026Conditions: Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD Interventions: Genetic: Ixo-vec; Drug: Aflibercept Sponsors: Adverum Biotechnologies, Inc. Recruiting
18 March 2026Conditions: GM1 Gangliosidoses; GM1 Gangliosidosis, Type I; GM1 Gangliosidosis, Type 2 Interventions: Drug: Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase..